thymocartin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	3033954
CHEMBL ID	2104516
SCHEMBL ID	443972
MeSH ID	M0133016

Synonyms (28)

Synonym
thymocartin
rgh-0206
thymocartinum [inn-latin]
thymocartin [inn]
thymocartina [inn-spanish]
rgh 0206
n-(n-(n(sup 2)-l-arginyl-l-lysyl)-l-alpha-aspartyl)-l-valine
thymocartine [inn-french]
l-valine, n-(n-(n(sup 2)-l-arginyl-l-lysyl)-l-alpha-aspartyl)-
l-valine, n-(n-(n2-l-arginyl-l-lysyl)-l-alpha-aspartyl)-
CHEMBL2104516
h-arg-lys-asp-val-oh
thymocartine
m0h0sk3ad5 ,
thymocartinum
thymocartina
unii-m0h0sk3ad5
85466-18-8
n-(n-(n2-l-arginyl-l-lysyl)-l-.alpha.-aspartyl)-l-valine
SCHEMBL443972
DTXSID20234688
(6s,9s,12s,15s)-1,6-diamino-9-(4-aminobutyl)-12-(carboxymethyl)-1-imino-15-isopropyl-7,10,13-trioxo-2,8,11,14-tetraazahexadecan-16-oic acid
rgh 0206; tp 4
Q27283305
(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoic acid
HY-105025
CS-0024724
AKOS040754200

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
" toxicity test on Wobe:BEAGLE dogs given daily doses of 6, 20 and 60 mg/kg of either test compound, no adverse reaction occurred."	( Preclinical toxicity studies with two thymopoietin-like peptides. Bodrogligeti, I; Cholnoky, E; Iván, E; Juhász-Nagy, A; Német, L, 1985)	0.27

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	5 (29.41)	18.7374
1990's	8 (47.06)	18.2507
2000's	2 (11.76)	29.6817
2010's	1 (5.88)	24.3611
2020's	1 (5.88)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.78 (24.57)
Research Supply Index	2.94 (2.92)
Research Growth Index	4.72 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.78)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	18 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
sb 202190 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase	2.25	1	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
suramin Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.	2.37	2	naphthalenesulfonic acid; phenylureas; secondary carboxamide	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
aspartic acid Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.	1.98	1	aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; mouse metabolite; neurotransmitter
mannitol [no description available]	2	1	mannitol	allergen; antiglaucoma drug; compatible osmolytes; Escherichia coli metabolite; food anticaking agent; food bulking agent; food humectant; food stabiliser; food thickening agent; hapten; metabolite; osmotic diuretic; sweetening agent
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	1.98	1	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
trifluoroethanol Trifluoroethanol: A non-aqueous co-solvent that serves as tool to study protein folding. It is also used in various pharmaceutical, chemical and engineering applications.	1.98	1	fluoroalcohol
lentinan [no description available]	1.97	1
splenotritin [no description available]	2.37	2	oligopeptide
thymopentin Thymopentin: Synthetic pentapeptide corresponding to the amino acids 32-36 of thymopoietin and exhibiting the full biological activity of the natural hormone. It is an immunomodulator which has been studied for possible use in the treatment of rheumatoid arthritis, AIDS, and other primary immunodeficiencies.	2.66	3	oligopeptide
oxazolone Oxazolone: Immunologic adjuvant and sensitizing agent.	1.96	1
rgh 0205 RGH 0205: RN given refers to all (L)-isomer	2.89	4	oligopeptide
vx-745 [no description available]	2.25	1	aryl sulfide; dichlorobenzene; difluorobenzene; pyrimidopyridazine	anti-inflammatory drug; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
pituitrin Pituitrin: A substance or extract from the neurohypophysis (PITUITARY GLAND, POSTERIOR).	1.98	1
mannans [no description available]	2.38	2

Condition	Relationship Strength	Studies
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	2.25	1
Astrocytoma, Grade IV [description not available]	2.25	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	2.25	1
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.11	1
Infections, Helicobacter [description not available]	2.11	1
Helicobacter Infections Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.	2.11	1
Armstrong Syndrome [description not available]	2.38	2
Metastase [description not available]	1.97	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	1.97	1
Delayed Hypersensitivity [description not available]	2.37	2
Cancer of Lung [description not available]	1.97	1
Lung Neoplasms Tumors or cancer of the LUNG.	1.97	1
Acute Liver Injury, Drug-Induced [description not available]	1.96	1
Eye Disorders [description not available]	1.96	1
Blood Diseases [description not available]	1.96	1
Nervous System Disorders [description not available]	1.96	1
Eye Diseases Diseases affecting the eye.	1.96	1
Hematologic Diseases Disorders of the blood and blood forming tissues.	1.96	1
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	1.96	1
Nervous System Diseases Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.	1.96	1
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	1.96	1

chemdatabank.com